Monitoring antifolate resistance in intermittent preventive therapy for malaria

Trends in Parasitology

Volumn 29, Issue 10, 2013, Pages 497-504

  Venkatesan, Meera ^a,b   Alifrangis, Michael ^c   Roper, Cally ^d   Plowe, Christopher V ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b WorldWide Antimalarial Resistance Network   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST;

ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; DRUG MONITORING; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MUTATION; PLASMODIUM; PREGNANT WOMAN; PRESCHOOL CHILD; PREVALENCE; PROPHYLAXIS; REVIEW;

PLASMODIUM FALCIPARUM;

EID: 84884414547     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.07.008     Document Type: Review

References (83)

1. Peters W. Chemotherapy and Drug Resistance in Malaria 1987, Academic Press.
2. Vleugels M.P., et al. Fansidar-resistant Plasmodium falciparum infection from Tanzania. Trop. Geogr. Med. 1982, 34:263-265.
3. Stahel E., et al. Pyrimethamine/sulfadoxine resistant falciparum malaria acquired at Dar es Salaam, Tanzania. Lancet 1982, 1:1118-1119.
4. Charmot G., et al. [2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation]. Bull. Soc. Pathol. Exot. Filiales 1987, 80:447-451. (in French).
5. Kupferschmidt H.G., et al. Chloroquine and fansidar resistance of Plasmodium falciparum now also in Ghana. Angew. Parasitol. 1988, 29:211-213.
6. World Health Organization Guidelines for the Treatment of Malaria 2006, World Health Organization.
7. World Health Organization World Malaria Report 2008, World Health Organization.
8. ter Kuile F.O., et al. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007, 297:2603-2616.
9. World Health Organization A Strategic Framework for Malaria Prevention and Control during Pregnancy in the African Region 2004, World Health Organization.
10. World Health Organization World Malaria Report 2011 2011, World Health Organization.
11. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi) 2009, World Health Organization Technical Expert Group on Preventive Chemotherapy, World Health Organization.
12. Aponte J.J., et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009, 374:1533-1542.
13. Wilson A.L. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE 2011, 6:e16976.
14. World Health Organization WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum Malaria Control in Highly Seasonal Transmission Areas of the Sahel Sub-region in Africa 2012, World Health Organization.
15. O'Meara W.P., et al. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect. Dis. 2010, 10:545-555.
16. Gesase S., et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS ONE 2009, 4:e4569.
17. Laufer M.K., et al. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. 2007, 77:160-169.
18. Cowman A.F., et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:9109-9113.
19. Peterson D.S., et al. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:9114-9118.
20. Peterson D.S., et al. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3018-3022.
21. Foote S.J., et al. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3014-3017.
22. Brooks D.R., et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 1994, 224:397-405.
23. Triglia T., Cowman A.F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:7149-7153.
24. Triglia T., et al. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13944-13949.
25. Wang P., et al. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol. 1997, 23:979-986.
26. Kublin J.G., et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
27. Plowe C.V. The evolution of drug-resistant malaria. Trans. R. Soc. Trop. Med. Hyg. 2009, 103(Suppl. 1):S11-S14.
28. Picot S., et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 2009, 8:89.
29. Grimberg B.T., Mehlotra R.K. Expanding the antimalarial drug arsenal - now, but how?. Pharmaceuticals (Basel) 2011, 4:681-712.
30. World Health Organization WHO Policy Recommendation on Intermittent Preventive Treatment During Infancy with Sulphadoxine-Pyrimethamine (SP-IPTi) for Plasmodium falciparum Malaria Control in Africa 2010, World Health Organization.
31. World Health Organization Report of the Technical Consultation on Defining and Validating a Measure of Parasite Resistance to SP Which Would be Indicative of the Protective Efficacy of SP-IPTi 2009, World Health Organization.
32. Naidoo I., Roper C. Mapping 'partially-resistant', 'fully-resistant', and 'super-resistant' malaria. Trends Parasitol. 2013, 10.1016/j.pt.2013.08.002.
33. Mockenhaupt F.P., et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J. Infect. Dis. 2008, 198:1545-1549.
34. Bouyou-Akotet M.K., et al. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. J. Antimicrob. Chemother. 2010, 65:438-441.
35. Alker A.P., et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob. Agents Chemother. 2005, 49:3919-3921.
36. Iriemenam N.C., et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar. J. 2012, 11:134.
37. Harrington W.E., et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9027-9032.
38. Kalanda G.C., et al. Comparative efficacy of chloroquine and sulphadoxine-pyrimethamine in pregnant women and children: a meta-analysis. Trop. Med. Int. Health 2006, 11:569-577.
39. Mutabingwa T.K., et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS ONE 2009, 4:e5138.
40. Tagbor H., et al. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet 2006, 368:1349-1356.
41. World Health Organization Technical Expert Group Meeting on Intermittent Preventive Treatment in Pregnancy (IPTp) 2007, World Health Organization.
42. World Health Organization Updated WHO Policy Recommendation: Intermittent Preventive Treatment of Malaria in Pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) 2012, World Health Organization.
43. Menendez C., et al. HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment. Clin. Infect. Dis. 2011, 52:41-48.
44. Taylor S.M., et al. Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Clin. Infect. Dis. 2012, 55:42-50.
45. Lin J.T., et al. Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria. Trop. Med. Int. Health 2013, 18:175-178.
46. ter Kuile F.O., et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am. J. Trop. Med. Hyg. 2004, 71:41-54.
47. Iyer J.K., et al. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001, 358:1066-1067.
48. Newman P.M., et al. Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar. J. 2009, 8:254.
49. Thera M.A., et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis. 2005, 192:1823-1829.
50. Malamba S., et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am. J. Trop. Med. Hyg. 2010, 82:766-771.
51. Malamba S.S., et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am. J. Trop. Med. Hyg. 2006, 75:375-380.
52. Pearce R.J., et al. A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. J. Infect. Dis. 2013, 207:848-859.
53. Dicko A., et al. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar. J. 2010, 9:9.
54. Institute of Medicine Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report 2008, National Academy of Sciences.
55. Kobbe R., et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 2007, 45:16-25.
56. Mockenhaupt F.P., et al. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop. Med. Int. Health 2005, 10:901-908.
57. Mayor A., et al. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J. Infect. Dis. 2008, 197:1737-1742.
58. Gosling R.D., et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1521-1532.
59. Pearce R.J., et al. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob. Agents Chemother. 2003, 47:1347-1354.
60. Griffin J.T., et al. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE 2010, 5:e12618.
61. Marks F., et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J. Infect. Dis. 2005, 192:1962-1965.
62. Faye B., et al. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol. Res. 2011, 109:133-138.
63. Djimde A.A., et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 2003, 69:558-563.
64. Raman J., et al. Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. Am. J. Trop. Med. Hyg. 2008, 78:256-261.
65. Mockenhaupt F.P., et al. Short report: high prevalence and imbalanced age distribution of the Plasmodium falciparum dihydrofolate reductase gene Asn108 mutation in an area of low pyrimethamine usage in Nigeria. Am. J. Trop. Med. Hyg. 1999, 61:375-377.
66. Enosse S., et al. Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malar. J. 2008, 7:115.
67. Staedke S.G., et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health 2004, 9:624-629.
68. Happi C.T., et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005, 95:183-193.
69. Cisse B., et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006, 367:659-667.
70. Dicko A., et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011, 8:e1000407.
71. Konate A.T., et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011, 8:e1000408.
72. Duah N.O., et al. Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana. Am. J. Trop. Med. Hyg. 2012, 87:996-1003.
73. Raman J., et al. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am. J. Trop. Med. Hyg. 2010, 82:788-794.
74. Raman J., et al. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS ONE 2011, 6:e25992.
75. Alifrangis M., et al. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am. J. Trop. Med. Hyg. 2009, 80:523-527.
76. World Health Organization Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010 2010, World Health Organization.
77. van Eijk A.M., et al. Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data. Lancet Infect. Dis. 2011, 11:190-207.
78. Naidoo I., Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology 2011, 138:1469-1479.
79. Zhou Z., et al. Decline in sulfadoxine-pyrimethamine-resistant alleles after change in drug policy in the Amazon region of Peru. Antimicrob. Agents Chemother. 2008, 52:739-741.
80. Bacon D.J., et al. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob. Agents Chemother. 2009, 53:2042-2051.
81. Plowe C.V., et al. World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar. J. 2007, 6:121.
82. Friesen J., et al. Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. Antimicrob. Agents Chemother. 2011, 55:2760-2767.
83. White N.J. Intermittent presumptive treatment for malaria. PLoS Med. 2005, 2:e3.